Literature DB >> 9274470

Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study.

S K Lam1, C K Ching, K C Lai, B C Wong, C L Lai, C K Chan, L Ong.   

Abstract

BACKGROUND: Treatment of Helicobacter pylori infection prevents duodenal ulcer relapse. It has not been established if treatment of the infection heals duodenal ulcer. AIM: To test the hypothesis that treatment of the infection was associated with healing of duodenal ulcer.
METHODS: A randomised, double blind placebo controlled trial was performed to study the efficacy of an antibiotic only regimen consisting of 300 mg metronidazole, 500 mg amoxycillin, and 250 mg clarithromycin, each given four times daily for two weeks, in the healing of duodenal ulcer as assessed by endoscopy. Symptoms were controlled with acetaminophen and antacids.
RESULTS: Of 100 consecutive patients with endoscopically established duodenal ulcer, 97 with positive rapid urease test on antral biopsy specimens were admitted into the study and 81 completed the trial. Of these, 40 were randomised to receive antibiotics and 41 to receive placebo. Treatment with antibiotics resulted in 92.5% (95% confidence interval (95% CI) 84.3-100) healing at four weeks and 100% at eight and 12 weeks; the corresponding healing rates for placebo treatment were respectively, 36.6%, 61%, and 63.4% (95% CIs 21.8-51.3, 46.0-75.9, and 48.7-78.2 respectively). The differences between the two treatment groups were significant at p < 0.001 at each time point and by life table analysis. Clearance of H pylori as assessed by urease test on antral biopsy specimens at four weeks and eradication of the organism as determined by 13C-urea breath test at eight weeks were achieved in 85% and 62.5% of patients respectively. Duodenal ulcer healed at four weeks in 87.2% and 86.2% (95% CIs 76.7-97.7 and 73.7-98.8) of patients in whom H pylori clearance or eradication, was achieved, versus 42.9% and 51.9% (95% CIs 27.9-57.8 and 38.3-65.5; p < 0.001 and < 0.003 respectively) in whom these processes failed. Stepwise discriminant analysis on 32 clinical, personal, and endoscopic characteristics as well as H pylori clearance and eradication identified H pylori clearance as the most discriminative variable for the healing of duodenal ulcer at four weeks, followed by ulcer depth and eradication of the organism.
CONCLUSIONS: Treatment with an antibiotic only regimen was effective for the healing of duodenal ulcer, and clearance as well as eradication of H pylori contributed significantly to the healing. The results constituted the strongest evidence to date that H pylori infection was aetiologically related to duodenal ulceration, and support the concept of treating duodenal ulcer associated with H pylori as an infection and relieving its symptoms with acid reducing agents such as antacids.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9274470      PMCID: PMC1027226          DOI: 10.1136/gut.41.1.43

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

1.  Metronidazole versus cimetidine in treatment of gastroduodenal ulcer.

Authors:  M Quintero Diaz; A Sotto Escobar
Journal:  Lancet       Date:  1986-04-19       Impact factor: 79.321

2.  A plea for the inclusion of a placebo group in duodenal ulcer trials.

Authors:  S K Lam
Journal:  Gastroenterology       Date:  1983-10       Impact factor: 22.682

3.  Placebos in clinical trials of duodenal ulcer: the end of an era?

Authors:  W L Peterson; J Elashoff
Journal:  Gastroenterology       Date:  1980-09       Impact factor: 22.682

4.  Smoking, nonsteroidal anti-inflammatory drugs, and acetaminophen in gastric ulcer. A study of associations and of the effects of previous diagnosis on exposure patterns.

Authors:  J H McIntosh; C S Fung; G Berry; D W Piper
Journal:  Am J Epidemiol       Date:  1988-10       Impact factor: 4.897

5.  Campylobacter pylori detected noninvasively by the 13C-urea breath test.

Authors:  D Y Graham; P D Klein; D J Evans; D G Evans; L C Alpert; A R Opekun; T W Boutton
Journal:  Lancet       Date:  1987-05-23       Impact factor: 79.321

6.  Treatment of duodenal ulcer with antacid and sulpiride. A double-blind controlled study.

Authors:  S K Lam; K C Lam; C L Lai; C K Yeung; L Y Yam; W S Wong
Journal:  Gastroenterology       Date:  1979-02       Impact factor: 22.682

7.  Gastric cytoprotection by amoxycillin in the rat.

Authors:  S K Lam; C H Cho; B W Chen; K C Lai; C K Ching; C S Ho; Y N Li
Journal:  J Gastroenterol Hepatol       Date:  1994 Sep-Oct       Impact factor: 4.029

8.  Accurate prediction of duodenal-ulcer healing rate by discriminant analysis.

Authors:  S K Lam; J Koo
Journal:  Gastroenterology       Date:  1983-08       Impact factor: 22.682

9.  Factors affecting the healing rate of duodenal and pyloric ulcers with low-dose antacid treatment.

Authors:  S Massarrat; A Eisenmann
Journal:  Gut       Date:  1981-02       Impact factor: 23.059

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  5 in total

1.  Gastroprotective effect of intragastric clarithromycin against damage induced by ethanol in rats.

Authors:  C A Gutiérrez-Cabano; A C Raynald
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

Review 2.  Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people.

Authors:  Alexander C Ford; Kurinchi Selvan Gurusamy; Brendan Delaney; David Forman; Paul Moayyedi
Journal:  Cochrane Database Syst Rev       Date:  2016-04-19

Review 3.  A rational approach to uninvestigated dyspepsia in primary care: review of the literature.

Authors:  N L A Arents; J C Thijs; J H Kleibeuker
Journal:  Postgrad Med J       Date:  2002-12       Impact factor: 2.401

4.  Strategies for peptic ulcer healing after 1 week proton pump inhibitor-based triple Helicobacter pylori eradication therapy in Japanese patients: differences of gastric ulcers and duodenal ulcers.

Authors:  Toshihisa Takeuchi; Eiji Umegaki; Nozomi Takeuchi; Yukiko Yoda; Yuichi Kojima; Satoshi Tokioka; Kazuhide Higuchi
Journal:  J Clin Biochem Nutr       Date:  2012-06-08       Impact factor: 3.114

5.  One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients.

Authors:  Iyad M Subei; Hector José Cardona; Ernesto Bachelet; Emerson Useche; Anthony Arigbabu; Adnan Abu Hammour; Tom Miller
Journal:  Dig Dis Sci       Date:  2007-04-27       Impact factor: 3.487

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.